ABSTRACT: New protecting group chemistry is used to greatly simplify imaging probe production. Temperature and organic solvent-sensitive biomolecules are covalently attached to a biotinbearing dioxaborolane, which facilitates antibody immobilization on a streptavidin-agarose solid-phase support. Treatment with aqueous fluoride triggers fluoride-labeled antibody release from the solid phase, separated from unlabeled antibody, and creates [ 18 F]-specific activity relative to solution-based radiosyntheses. Two applications are investigated: an anti-epithelial cell adhesion molecule (EpCAM) monoclonal antibody (mAb) that labels prostate tumors and Cetuximab, an anti-epidermal growth factor receptor (EGFR) mAb (FDA approved) that labels lung adenocarcinoma tumors. Colocalized, tumor-specific NIRF and PET imaging confirm utility of the new technology. The described chemistry should allow labeling of many commercial systems, diabodies, nanoparticles, and small molecules for dual modality imaging of many diseases.
■ INTRODUCTION
Aryl dioxaborolanes play an important role in molecular imaging, with notable applications in peroxide sensing, 1−3 positron emission tomography, 4−6 and multimodality imaging. 7 These highly nucleophile-selective dioxaborolanes can be additionally modified for more complex application. New chemistry is described for incorporating dioxaborolanes into fluoride-reactive, chloride-ion inert, cleavable linkers. These bisfunctionalized synthons improve upon silicon-based fluoride-reactive linker technology 8, 9 and have added utility in 18 F-PET. Cleavable linkers have application in a broad range of chemical biology applications including proteomics, imaging, and sequencing. 10 Dioxaborolanes can be incorporated into novel immobilization chemistry to greatly simplify the generation of multimodality [ 12−19 because it is bioorthogonal and unique to boron.
A bioorthogonal radiolabeling strategy must occur in conditions that are not detrimental to biomolecule activity. Monoclonal antibodies (mAbs) are ideal biomolecules for testing bioorthogonality, as they are inexpensive, and have mAb-antigen specificities that are more sensitive to denaturation in organic solvents and high temperatures than small molecules. 18 F has a short decay half-life that does not match the long biological half-life of antibodies, resulting in imperfect, [ 20 since NIRF probes do not decay like radioisotopes. For reasons like these, PET/NIRF multimodality imaging is superior to standalone SPECT, PET, and NIRF in all its facets, including depth-of-penetration, spatial, and temporal resolution. 7, 21 Hendricks et al. has set precedent by being the first group to demonstrate multimodality [ 18 F]-PET/fluorescent labeling on [ 18 F]-PET/BODIPY-labeled, systemically injected, Herceptin mAb. 15 We build on this PET/fluorescent-mAb precedent with new bioorthogonal aryl dioxaborolane chemistry that additionally incorporates a near-infrared fluorophore and novel dioxaborolane cleavable-linker technology. Fluoride-triggered dioxaborolane decomposition is so mild that mAbs can be fluoridated directly, without inhibiting antigen binding. The new technology is verified on two commercially available mAbs for imaging prostate (PC3) 22 or lung (A549) cancers in vitro and in vivo. Enough [ 18 F]-labeled mAb is generated for systemic injection in seven mice. Four mice are simultaneously [ 18 F]-PET imaged on an Inveon PET/CT (Video S1). The design of compound 1 (Figure 1 , Scheme S2) centers on a dioxaborolane that is functionalized so that a boron atom serves as a fluoridereactive, critical link between our tracer and a solid phase. We mimic the current strategy utilized in 99m Tc SPECT radiosynthesis using [ 18 F]-fluoride, a clinically unique PET isotope. 23, 24 We choose to investigate a systemic mAb application due to the abundance of PET/NIRF literature on the topic. 25−27 The reported boronate chemistry is generally applicable to other biomolecules including other [ 18 F]-PET/NIRF-mAbs that can be used additionally in other nonsystemically delivered applications, like lymphatic mapping and drug delivery. 28, 29 ■ RESULTS Syntheses and Small Molecule Reactivity. Dioxaborolane 1 is modified at boron with both a heptamethinecyanine-NIR fluorophore and an NHS ester so that 1 can be generally applied to amine-bearing targets for multimodality imaging. Biotinylation of the dioxaborolane's 1,2-diol gives a prototype for solid-phase, streptavidin-agarose labeling. A thiol-reactive maleimide derivative of 1, Mal-1, is also synthesized (Figure 1 , Figures S1−S2).
Small Molecule, Solid-Phase Capture and Release. The reaction of solid-phase-bound 1 with aqueous fluoride achieves two simultaneous events: the generation of 2, a free trifluoroborate imaging agent that can no longer bind streptavidin-agarose, and the release of 2 from the solid phase. Unreacted, non-fluoride-bearing 1 remains bound to the solidphase, resolved from fluoride-bearing 2 ( Figures S1−S4 ). The conversion of streptavidin-agarose bound Mal-1 into free Mal-2 is achieved at room temperature in 40 min with 13.4 mM HF (pH 3.0). Eluted Mal-2 contains only 10% of the 750 nm absorbance, a majority of Mal-1 absorbance remains bound to streptavidin-agarose as the biotinylated starting material, Mal-1. No Mal-1 was detected in the eluent by HPLC ( Figure S4 ). This reusable, dioxaborolane containing matrix can be flushed with [ Solid-Phase mAb Capture and Fluoride Specific Elution. The mild conditions associated with solid-phase attachment and fluoride elution encourage us to apply this chemistry to complex biological targets. Two commercially available mAbs for imaging prostate (anti-EpCAM mAb) 22 or lung (Erbitux) cancers could be labeled with 2 equiv of 1 in mild conditions (Scheme S1) to give mAb-1 in <1 h ( Figure S5 ). mAb-1 is functionalized on streptavidin-agarose at 14 ± 5 pmols mAb-1 per μL ( Figure S6 ) and reacted with acidic fluoride to give mAb-2 in <1 h (Figure 2) . Centrifuge-based, solid-support elution of mAb-2 is fast, separates mAb-2 from mAb-1, and is F-PET/NIRF probe. The amide reactive 18 F-PET/NIRF precursor, 1, the maleimide precursor, Mal-1, and the monoclonal antibody conjugate, mAb-1 (EpCAM) or Cetuximab-1 as R groups (left panel). A fluoride-labile, mAb-1-bearing, solid support is generated when the N-hydroxy succinimide ester (NHS)/maleimide precursor is reacted with mAb and then exposed to a streptavidin bearing support. mAb that is not covalently attached to 1 cannot be retained by the support and is removed with washing. Treatment of the solid support with aqueous fluoride achieves conversion of 1 into a 18/19 F labeled trifluoroborate 2, a species useful for PET/NIRF multimodality imaging and simultaneous release of 18 F-PET/NIRF labeled mAb-2 from the solid support. Unreacted mAb-1 remains bound to the support through the biotin handle on the solid-phase support (Scheme S1). F]-sodium fluoride were reacted with mAb-1, the greatest specific activity syntheses were observed when mAb-1 is directly fluoridated on streptavidinagarose (4.9 mCi/μmol is obtained (t = 220 min) ( Figure S12) ). 
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Article This was 13-fold better than obtained when streptavidinagarose is not employed, i.e., the solid support was not used to remove mAb and mAb-1 (0.38 mCi/μmol is obtained (t = 220 min) ( Figure S10 , Scheme S4a)) and 6.4-fold better then when streptavidin-agarose is added to a premixed mAb-1 [ 18 F]-fluoride solution, i.e., the solid support was not used to remove mAb (Scheme S4b, Figures S11, S13, S14). mAb-2 Generation Does Not Alter in Vitro mAb Binding. During a multistep synthesis and purification, a mAb can be denatured and/or chemically modified to eliminate antigen binding. For mAb-2 to be useful for imaging, mAb antigen-binding must be preserved in all steps of the radiosynthetic scheme, including NHS-ester reaction of 1 with mAb, mAb-1 immobilization on streptavidin-agarose, fluoride-triggered release of mAb-2, and SEC HPLC purification (Scheme S1). 18 F]-PET imaging was performed on orthotopic A549 lung tumors. The orthotopic lung tumor model is a challenging model for PET imaging as the lung is a low density structure that is better imaged with a low positron-energy emitter, like 18 F. The tumor is located close to many tissues with high contrast content. There are two major advantages to choosing a orthotopic lung model over the standard subcutaneous flank model: (1) the biology of the xenographed tissue is more representative to that of its target tissue, and (2) orthotopic A549 tumors reliably metastasize into the lung, unlike PC3 subcutaneous tumors that metastasize unpredictably. Eight mice were inoculated with A549 cells expressing luciferase and GFP by transpleural injection through the left rib cage. Bioluminescence imaging was used to verify a chest-wall, primary tumor, which is also visible by CT (0.5 cm diameter, Figure 6a,b) . Figure 6f ). Cetuximab-2, Cy7 fluorescence is visible in the primary and metastatic lung tumors but is heterogeneously distributed. Heterogeneous A549 GFP expression is confirmed on high-magnification fluorescence histology (Figure 6i,j) . These local, nonhomogeneous distributions complicate the reconciliation of whole organ scintillated biodistribution with the high-resolution fluorescent Cetuximab-2 data. Nevertheless, standard scintillation and ROI analyses (%ID/g in Figure 6g and %ID in Figures S19, S20) show significant difference between [ 
Article enough for multiple animal imaging (Videos S1,S2), allowing us to consider advanced antibody imaging studies in more than seven mice from a single, 150 mCi dose of evaporated [ 
■ DISCUSSION
A bioorthogonal method for specific, covalent bond cleavage using inert fluoride ion is described. Boron-based fluoride capture allows the radiolabeling of mAbs without organic solvents and/or high temperatures. This treatment does not affect mAb-antigen affinity as verified by fluorescence microscopy and fluorescence assisted cell counting. Immobilization of mAb-1 to streptavidin-agarose, solid phase allows for direct fluoridation that simultaneously generates [ F (2 Ci) or by reformulating synthon iii (Scheme S2) as alkyl boronates. 6 Alternatively, this technology was designed with aqueous electrowetting dielectric microfluidic (EWOD) compatibility in mind. 34 EWOD can generate specific activities upward of 20 Ci/μmol on a small molecule starting from just 8 mCi of activity. 34 Higher specific activities may limit fluorescent visibility on PET/FL probes. 35, 36 Previous strategies for generating 18 F-mAbs require multiple synthetic steps; solvent/phase transfers, large activities, robotic manipulation, and automation that must be performed in the face of rapid 18 F-precursor decay. The chemistry described here is unique, as enough 18 F labeled mAb activity is generated for a comprehensive 18 F-mAb analysis in seven mice. This is the second study to demonstrate the in vivo imaging of a 18 F-PET/ FL-mAb. 15 The chemistry described here is achieved without the use of organic cosolvents or higher temperatures, making this labeling strategy ideally compatible with antibodies, biological molecules, and holocomplexes, agents that are particularly sensitive to precipitation and denaturation when heated or exposed to organic solvents. This strategy also incorporates 18 F in a final step, allowing one to save valuable time by avoiding the purification of preconjugates. The sulfonated heptamethine cyanine, and biotinylated precursor 1, was deliberately designed to be more water-soluble than maleimidyl, DBCO-click, and inverse electron demand Diels-Alder (tetrazine) pretargeting systems. This is advantageous, as cosolvents that are required to solubilize these chemistries can denature or inactivate complex biomolecules.
Cetuximab is clinically relevant, and is inexpensive relative to mAb fragments for developing new radiochemistry. There are many literature reports of Cetuximab PET imaging. For these reasons, we found Cetuximab to be more appropriate than small molecules or reengineered mAbs as a surrogate for demonstrating biocompatible dioxaborolane chemistry. We note that the choice to image a systemic mAb is not ideal (in a clinical, systemic application), as the half-life of fluoride-18 (110 min) and mAb biodistribution (>12 h) do not match prima facie. 31, 32 Conventional thinking suggests that fluoride-18 is more suited for imaging diabodies and antibody fragments, Alternatively, a mAb that is reengineered will not accurately represent the distribution and clearance of its therapeutic, clinical mAb counterpart. This is problematic if one wished to use the fluorescence component of a PET/NIRF mAb fragment to image (1) antigen binding and endocytosis in histology; (2) homogeneous mAb distribution to antigen expressing cells/ distribution of a mAb therapeutic to the margins of a tumor; or (3) striated or streamlined routes of mAb clearance that may minimize distribution of a mAb drug to a tumor (and would counterproductively encourage chemoresistance). For these situations one may consider a third alternative; the 89 Zr-PET/ NIRF labeled mAb. Unfortunately, the drawback to PET imaging is that multiple radioactive isotope labeled antibodies cannot be imaged in parallel, and one must wait for individual isotope decay before a second radioactive isotope labeled antibody is imaged. This is relevant in imaging intratumoral heterogeneity 37 ( Figure 6d−j) , where a tumor may respond to two or more mAb therapies. Awaiting isotope decay can translate into weeks between 89 Zr scans, which is prohibitive in imaging a fast-growing tumor. Given these caveats, one may wish to consider a [
18 F]-PET/NIRF-mAb, where a short-lived PET isotope would rapidly decay, allowing the prompt, next day imaging of another antibody.
Reduction in radioactive signal for PET imaging over time is problematic, but is compensated by the use of fluorophores (FLs), which retain fluorescence imaging capability far beyond the temporal window of radioactive isotope decay. Additionally, PET/FL probes can be screened in parallel using different antibodies labeled with multiple, spectrally distinct fluorophores for simultaneous imaging of multiple antigens. Unfortunately, the in vivo fluorescence quantification of a [ 18 F]-PET/NIRF-mAb would require fluorescent endoscopy. This is debatably less invasive than the PET radiation incurred from multiple back-toback 89 Zr antibody scans, but would accurately predict in vivo distributions of therapeutic antibodies like Erbitux. NIRF imaging of antigen-positive tumor resections ( Figure 6 ) is used to corroborate in vivo PET imaging, and NIRF is capable of spatial resolution (Figure 4 ) that greatly exceeds that of PET. 15 The ability to image heterogeneity in tumor histology, even after quantitative [ 18 F]-isotope decay, 7 adds another dimension to PET/NIRF imaging that cannot be observed with the inferior resolution of PET scintillated biodistribution alone.
The successful transformation of an antibody into a multimodality imaging agent highlights this technology's clear, nondenaturing potential on contrast agents with current, therapeutic utility. 38−40 This technology is not limited to systemic mAbs injections, and sets a precedent for the conjugation of 1 and Mal-1 to amine and thiol containing agents, respectively, including commercially available Abs, diabodies, 41−43 nanobodies, nanoparticles, and small molecules for the dual modality imaging of a vast number of cancer biomarkers and diseaserelated proteins to many human maladies.
■ EXPERIMENTAL PROCEDURES mAb/Cetuximab Labeling with the Boronate/NIRF Probe, 1. 1 (1 μL, 2100 pmol, 2.1 mM in DMSO) was added to 62.5 μL of a 20 μM mAb solution (1250 pmol, EpCAM/ TROP1 mAb (Clone 158206, R&D systems, MAB9601) or Erbitux (Cetuximab, ImClone). Amide bond formation was initiated with 2.6 μL of 910 mM N-methylmorpholine (NMM) with total volume of 66.1 μL containing 31.8 μM 1, 18.9 μM mAb, and 35.8 mM NMM for 1 h. Absorbance based quantification gave 1−2 molecules of Cy7 per mAb. mAb-1/ Cetuximab-1 synthesis was verified by SEC HPLC on a Shodex 802.5, 400 Å, 300 cm × 8.0 mm silica hydrophilic polymer column (F6989000) using an isocratic solution of 250 mM PBS (pH 7.5) and a flow rate of 1 mL/min mAb-1/ Cetuximab-1 elutes between 5 and 7 min mAb-1/Cetuximab-1 labeling was also verified by PAGE (Figure 2) . mAb-1/ Cetuximab-1 is visible by Cy7 fluorescence (CRI Maestro full field fluorescence imager; excitation/emission of 730(42)/ 800LP).
Solid-Phase mAb-1/Cetuximab-1 [ 18/19 F]-Generator Construction. 19.5 μL of mAb-1/Cetuximab-1 (372 pmol) was added to 30 μL streptavidin-agarose (Solulink, N-1000-005) and incubated for 5 min. The mixture was transferred to a Spin-X 0.22 μm cellulose acetate filter (Costar, 8161) or a microspin column (30 μm polyethylene filter, Thermo Scientific, 89879) and was centrifuged at 4000 rcf for 1 min. The filtrate was discarded and streptavidin-agarose was resuspended in 500 μL of diH 2 O. The streptavidin-agarose was washed 3× 500 μL diH 2 O to completely remove unconjugated mAb and PBS buffer from mAb-1/Cetuximab-1.
Fluoride-Triggered mAb-2 Release from StreptavidinAgarose. Dry, mAb-1/Cetuximab-1-bound streptavidinagarose was resuspended in 70 μL of diH 2 O, and distributed into 12, 5 μL aliquots to microspin columns (Thermo Scientific Pierce). HF (concentrations listed in Figure 2 ) was added to the microspin columns to give a final volume of 15 μL (pH 3). Fluoridation proceeded for 15 min and reactions were quenched with 10 μL of 1 M PBS (pH 7.4). Microspin columns were centrifuged at 4000 rcf for 1 min to elute mAb-2/Cetuximab-2, which was analyzed by SEC HPLC or PAGE.
Solid-Phase, In Vivo Fluorescent Imaging of Tumors and Metastases Using mAb-2. 1.5 million PC3 cells were mixed with Corning matrigel matrix (4 mg/mL final concentration) in a total volume of 40 μL. This 40 μL mixture was injected subcutaneously into the lateral, dorsal, lower left flank of athymic nude mice. Tumors were grown for 16 weeks (diameter = 0.5 cm). Mice were anesthetized with 2% isoflurane at a 2 L/min flow and mAb-2 (90 μg, 600 pmols) was introduced through an i.v. tail vein injection. Isoflurane anesthetized mice on a heated pad were imaged at multiple time points (Figure 6 , Figures S18, S19) using a CRI Maestro in vivo, full field fluorescence imaging device. FP/dye was imaged with the following filters: DsRed2 excitation/emission of 530(52)/580LP nm, respectively, and liquid crystal = 590 nm. Cy7 was imaged using an excitation/emission of 730(42)/ 800LP nm and liquid crystal = 810 nm.
In Vivo PET/NIRF Imaging and Scintillation of Primary and Metastatic Tumors Using [
18 F]-Cetuximab-2. Animals were anesthetized with 2% isoflurane and placed in a lateral decubitus position. Two million A549 cells expressing luciferase and GFP (35 μL) were mixed with 35 μL matrigel and then directly injected into the chest wall/pleural cavity to a depth of 6 mm using a 25 G needle through the intercostal space on the left rib cage below the clavicle and just right of the left anterior axillary line. Mice were placed on a heating pad until recovered. Tumors were grown for 5 weeks (diameter = 0.5 cm). Mice were anesthetized with 2% isoflurane and [
18 F]-Cetuximab-2 (25−100 μCi, 10 μg/mouse) was introduced through an i.v. tail vein injection. Mice were fixed on trays such that up to four mice could be imaged simultaneously along with a 200 mL flask containing ∼40°C water in a Siemen's Inveon PET/CT. A 10 min CT scan and a 60 min PET scan was acquired 1.5 and 4.5 h following injection. Biodistribution was performed at 2.5 (n = 3) or 6 (n = 4) hours post injection. PET/CT were processed with Amide v 1.0. 4 Figure S1 . Mal-1 synthesis and aqueous conversion into the trifluoroborate, Mal-2. Figure S2 . Reactions of Mal-1 with various concentrations of fluoride. Figure S3 . Fluorescence imaging of Mal-1-biotin capture on magnetic streptavidin-IO (str-IO) particles (pH 7.4). Figure S4 . Fluoride triggered elution of Mal-2 from Mal-1 bound streptavidinagarose. Figure S5 . SEC HPLC analyses of mAb and mAb-1. Figure S6 . PAGE gel demonstrates mAb-1 binding to streptavidin-agarose. Figure S7 . Coomassie stained gel demonstrating the lack of nonspecific binding between unreacted mAb and streptavidin-agarose. Figure S8 . HPLC confirmation of the quantitative conversion of 1 into its trifluoroborate, 2. Figure S9 . SDS-PAGE gel of mAb-2 demonstrating a lack of binding between 37 pmols mAb-2 and streptavidin-agarose. 
